HomeTopic Collection
Topic Collection
Nanomedicine in Oncology
In the past few decades, significant progress has been made in the treatment and diagnosis of tumours. However, side effects, drug resistance and early-stage diagnosis remain challenges that will dampen the clinical outcomes. Nanomedicine that uses nanobiotechnology to deliver anti-cancer drugs or bioimaging reagents has had a great impact on the diagnosis and treatment of cancer, e.g., Abraxane, Doxil, Ferumoxsil etc. In the meantime, cancer immunotherapy has generated durable tumour inhibition. However, the initial success was dampened by its low response rate.
Guest Editors
Prof. Andrew Wang
The University of Texas Southwestern Medical Center Medical School, USA
https://orcid.org/0000-0002-9781-4494
Prof. Yuanzeng Min
University of Science and Technology of China, China
https://orcid.org/0000-0001-5030-0210
Prof. Clare Hoskins
University of Strathclyde Glasgow, UK
https://orcid.org/0000-0002-7200-0566
We are pleased to offer a 25% discount on the Article Processing Charge (APC) for articles submitted to this Topic Collection. Please visit our author hub for more information about the benefits of submitting to a Topic Collection.
With respect to this topic, we will put together the most recent research on nanomedicine in cancer therapy and diagnosis and their potential applications in clinical translation. We will also present current advances in nanobiotechnology in improving cancer immunotherapy. In addition, this topic will include nanobiotechnology in monitoring immune responses, which would guide clinical practice.
Submissions on the following topics are welcome:
- Utilization of nanotechnology in the delivery of anti-cancer drugs or bioimaging reagents
- Applications of nanotechnology in the diagnosis and treatment of cancer
- Advances and development of nanomedicine for cancer treatment
- Nanobiotechnology used for monitoring immune responses
Please see the instructions for authors for submission requirements for each article type. To submit your article, please follow these instructions and select ‘Nanomedicine in Oncology’ as the Topic Collection.
All submitted articles will be subject to the journal's normal peer review process. The Editor in Chief is responsible for the content of this Topic Collection. Guest Editors will manage peer review, invite reviewers and make a recommendation, but the final decision on all manuscripts will be made by the Editor-in-Chief.
Articles accepted for publication will be published upon acceptance. Visit our author hub for more information regarding the publication process for topic collections. Authors submitting to this Topic Collection are entitled to a 25% discount on the Article Processing Charge. Discount is available upon request to info.bmjonc@bmj.com.
For any inquiries regarding this topic collection, please contact topic.collections@bmj.com.
Keywords: Nanomedicine, Chemoradiotherapy, Drug Delivery, Gene Therapy, Cancer Immunotherapy, Photodynamic therapy, Bioimaging, Nanobiotechnology